As part of the reignited Cancer Moonshot, CancerX aims to leverage digital technologies to tackle some of the biggest challenges in cancer. To find out more, pharmaphorum editor-in-chief Jonah Comstock caught up with the ringleaders behind the ambitious effort
While targeted therapies have improved cancer patient outcomes, their efficacy decreases over time as patients develop resistance to the treatments. Steven Powell, president of Ribonexus, explores promising avenues of attack to combat cancer drug resistance